Unipolar Depression | Current Treatment | EU5 | 2017

The treatment landscape for major depressive disorder (MDD), consists of numerous safe and effective treatment options, many of which are available as inexpensive generics. Therapies to treat MDD span multiple drug classes, most notably selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs), while other agents, including the newer-to-market Brintellix (Lundbeck’s vortioxetine), offer distinct mechanisms of action; atypical antipsychotics are typically prescribed for patients with a poor response to antidepressants. Ultimately, given the multitude of drugs available to treat depressive symptoms, coupled with the heterogeneous nature of the patient population, treatment is often a trial-and-error process. As such, the treatment algorithm is complex and highly individualized.


  • What are the drivers and constraints influencing physicians’ treatment decisions for MDD across the EU5? How are patients being treated across different lines of therapy?
  • What drives switching to and from specific brands (e.g., Brintellix [Lundbeck], Cymbalta [Eli Lilly])? How has the availability of generic versions of Cymbalta (duloxetine) and Otsuka’s Abilify (aripiprazole) impacted prescribing?
  • To what extent is polypharmacy prescribed for MDD in the EU5 markets, and what are physicians’ preferred drug class combinations?
  • How has use of key MDD therapies changed in the past year, and what changes do physicians expect in their prescribing of these drugs in one year?


Current Treatment: Provides physician insights on prescribing behavior, treatment paths, and the factors and perceptions driving brand usage so you can understand each brand’s performance and improve or defend your competitive position.

Login to access report